Bessemer Group Inc. Acquires 259,124 Shares of Ingevity Corporation $NGVT

Bessemer Group Inc. grew its holdings in Ingevity Corporation (NYSE:NGVT) by 465.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 314,739 shares of the company’s stock after acquiring an additional 259,124 shares during the period. Bessemer Group Inc.’s holdings in Ingevity were worth $22,419,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in NGVT. Principal Financial Group Inc. raised its stake in Ingevity by 269.9% during the 4th quarter. Principal Financial Group Inc. now owns 652,237 shares of the company’s stock valued at $38,599,000 after purchasing an additional 475,907 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Ingevity by 311.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 600,380 shares of the company’s stock worth $23,769,000 after purchasing an additional 454,579 shares during the period. Simcoe Capital Management LLC grew its holdings in Ingevity by 188.8% during the 2nd quarter. Simcoe Capital Management LLC now owns 624,935 shares of the company’s stock valued at $26,928,000 after buying an additional 408,508 shares in the last quarter. Boston Partners grew its holdings in Ingevity by 141.6% during the 4th quarter. Boston Partners now owns 620,360 shares of the company’s stock valued at $36,719,000 after buying an additional 363,584 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Ingevity by 137.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 424,038 shares of the company’s stock valued at $25,095,000 after buying an additional 245,620 shares during the last quarter. Institutional investors own 91.59% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Ingevity in a report on Tuesday, April 21st. Wall Street Zen raised shares of Ingevity from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 7th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $80.00.

Ingevity Price Performance

NYSE:NGVT opened at $76.47 on Friday. The company has a current ratio of 1.42, a quick ratio of 0.92 and a debt-to-equity ratio of 27.83. The company has a market capitalization of $2.66 billion, a P/E ratio of -21.54 and a beta of 1.16. Ingevity Corporation has a 12 month low of $39.74 and a 12 month high of $79.29. The business’s 50-day moving average is $70.78 and its 200 day moving average is $70.10.

Ingevity (NYSE:NGVT) last released its quarterly earnings results on Wednesday, May 6th. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.31. The business had revenue of $258.00 million during the quarter, compared to analysts’ expectations of $254.73 million. Ingevity had a positive return on equity of 207.82% and a negative net margin of 10.55%.The firm’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter last year, the business posted $1.01 EPS. Ingevity has set its FY 2026 guidance at 4.700-5.200 EPS. On average, equities research analysts forecast that Ingevity Corporation will post 5.05 earnings per share for the current fiscal year.

Insider Activity at Ingevity

In other news, SVP Terrance M. Dyer sold 496 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $68.49, for a total transaction of $33,971.04. Following the completion of the transaction, the senior vice president directly owned 7,202 shares in the company, valued at approximately $493,264.98. This represents a 6.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.88% of the company’s stock.

Ingevity Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.